Search the webpage

Category: Custom R&D Projects
Animals used for research:   Mouse, Rabbit, Rat  

Experimentica’s Research & Development Division is actively developing novel in vivo models for a number of indications. Some of our current activities include the development of artificial corneas for permeability screening, development of standardized and validated readouts in novel models for diabetic retinopathy, identification of pathophysiological processes in meibomain gland dysfunction, and innovative approaches to induce demyelination of the optic nerve to mimic optic neuritis.

Utilizing state-of-the-art technology for the longitunial in vivo imaging of ocular tissues, such as spectral-domain ocular coherence tomography, fluorescein angiography and vitreofluorophometry, paired with traditional histological and molecular readout, we are able to detect early patholofical changes with unprecedented accuracy.

We look forward to an opportunity to partner with you to refine or develop almost any custom in vivo project. Over the years, we have worked with numerous pharmaceutical and biotech companies and academic institutions to either implement models previously described in the scientific literature or to develop novel models for ophthalmic disease indications.

SUMMARY

Animal species

Mouse, Rabbit, Rat.

Method of induction

Chirurgical or mechanical damage, lasering, intravitreal or subretinal injections of specialized compounds, exposure to external factors.

Follow-up period

Up to 12 months.

Route of compound administration

Topical, intravitreal injection, intravenous, systemic.

Read-outs

1. In vivo imaging:
    fundoscopy;
    fluorescein angiography;
    optical coherence tomography (OCT);
    vitreofluorophotometry.

 

2. In vivo functional assessment (behavioral analysis and scoring, electroretinogram and visually-evoked potentials)

 

3. Morphological assessment (histology, immunohistochemistry, electron microscopy, stereology)

 

4. Molecular biology (ELISA, Western blotting, qPCR)

Please contact us, if you would like to receive more information: info@experimentica.com

IMAGES

Experimentica's Preclinical Development Pipeline

Our Preclinical Development Pipeline allows you to take your drug candidates from mechanistic in vitro studies through preclinical pharmacology to GLP tolerability and toxicology studies.

SELECTED PUBLICATIONS

  • Ragauskas S, Kielczewski E, Vance J, Kaja S, Kalesnykas G. In vivo multimodal imaging and analysis of mouse laser-induced choroidal neovascularization model. J Vis Exp (131), e56173. DOI:10.3791/56173 (2018).
  • Tuomela A, Liu P, Puranen J, Rönkkö S, Laaksonen T, Kalesnykas G, Oksala O, Ilkka J, Laru J, Järvinen K, Hirvonen J, Peltonen L. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo. Int J Pharm. 2014 Jun 5;467(1-2):34-41.

REFERENCES

  • Hakkarainen JJ, Reinisalo M, Ragauskas S, Seppänen A, Kaja S, Kalesnykas G. Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells. International Journal of Pharmaceutics 2016; 511:73-78.
  • Ragauskas S, Leinonen H, Puranen J, Rönkkö S, Nymark S, Gurevicius K, Lipponen A, Kontkanen O, Puoliväli J, Tanila H, Kalesnykas G. Early Retinal Function Deficit without Prominent Morphological Changes in the R6/2 Mouse Model of Huntington’s Disease. PLoS One. 2014 Dec 3;9(12):e113317.

LATEST NEWS

Advances in preclinical in vivo imaging: OCT-Angiography of the rat retina

News
OCT-Angiography (OCT-A) scan of the adult rat retina. Already routinely used in the clinical setting, this non-invasive imaging technique to ... Read More

Experimentica at Bio Partnering event in Shanghai 2019

News
Experimentica Ltd. participates at Bio Partnering APAC conference in Shanghai, China, on September 24-25, 2019 ... Read More

Visit our poster in 17th European Congress of Toxicologic Pathology

News
Experimentica's partner Aiforia Technologies Oy will present joint poster dedicated for illustration of the effectivity of Aflibercept, administered systemically and ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!